Hematologic Oncology

In this podcast from the 2014 American Society of Hematology Annual Meeting, we discuss some of the new developments in multiple myeloma.

The FDA has approved blinatumomab (Blincyto) for the treatment of patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia.

Early trial data support further evaluation of ixazomib combined with lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma.

Ahead of the 2014 ASH Annual Meeting & Exhibition we discuss current treatment strategies for elderly patients with acute myeloid leukemia.

Non-germinal center B-cell-like DLBCL patients derived the most benefit from treatment with the immunochemotherapy regimen R-ACVBP compared with R-CHOP.

Elderly patients with poor-prognosis DLBCL may derive the most benefit from treatment with extended rituximab plus 6 cycles of R-CHOP on a 14-day schedule.

A 48-year-old man presents with diffuse lymphadenopathy. After further evaluation, a biopsy is performed. What is your diagnosis?

Adding the HDAC inhibitor valproic acid to decitabine did not improve outcomes in patients with myelodysplastic syndromes or acute myeloid leukemia.

Hispanic childhood cancer survivors are less likely to receive follow-up care later in life than white survivors, according to a new study.

Survivors of multiple myeloma and pancreatic cancer may have some of the poorest physical health-related quality of life outcomes, according to a new study.

Patients who experienced early relapse of multiple myeloma after undergoing autologous stem cell transplantation had worse progression-free and overall survival.

Survivors of childhood Hodgkin lymphoma who went on to regularly complete vigorous exercise had a lower risk of cardiovascular events later in life.

Ninety percent of patients with relapsed/refractory acute lymphoblastic leukemia achieved complete remission after a T-cell therapy treatment targeting CD19.

Monitoring minimal residual disease and real-time quantitative polymerase chain reaction can predict relapse in pediatric acute lymphoblastic leukemia patients.

A phase III trial of vosaroxin failed to meet its primary overall survival endpoint in patients with first relapsed or refractory acute myeloid leukemia.

Myeloma patients treated with melphalan prior to transplant had reductions in chemo-induced nausea/vomiting when given granisetron/dexamethasone and aprepitant.

In this interview we discuss the use of newly approved agents for chronic lymphocytic leukemia, next-generation therapies in the pipeline, and how the treatment of this type of leukemia has changed.

A regimen of gemcitabine/dexamethasone/cisplatin was as effective and less toxic than the current standard of care for treating relapsed, refractory lymphoma.

Panobinostat added to bortezomib/dexamethasone for treating relapsed/refractory multiple myeloma improved progression-free survival and complete response rates.

Patients with non-high-risk APL can achieve better clinical outcomes when treated with ATRA plus arsenic trioxide compared with ATRA plus chemotherapy, a new study found.

Data from a pooled analysis show that PET-CT provided better response assessment than did CT and predicted inferior survival in follicular lymphoma patients.

Hodgkin lymphoma survivors who were treated with infradiaphragmatic radiotherapy have an increased risk of developing diabetes mellitus, says a new study.

A study of more than 4,500 patients with acute myeloid leukemia (AML) found that predicting resistance to therapy remains an elusive practice.

Multiple myeloma patients may already suffer from sensory deficits prior to treatment, likely due to disease-related decreases in peripheral innervation density.

The rationale for maintenance therapy in indolent non-Hodgkin lymphoma was derived from historical data suggesting that despite robust response rates to standard therapy, most patients eventually relapse and disease-free intervals become progressively shorter.